

Clearly Focused on You

eye care
associates, inc.

iStent® Trabecular Micro-Bypass

iStent® Trabecular Micro-Bypass

Technology has always played an important role in eye care. Today, almost every aspect of vision is connected to a product or procedure that wasn't available even ten short years ago. Cataract surgery is a good example of how innovations can make a difference. Every aspect of it utilizes recently developed technology that helps us improve your vision. Today, this includes managing your mild-to-moderate open-angle glaucoma: because now we are able to add another step to cataract surgery that allows us to treat open-angle glaucoma in a completely new way. This is important because most patients with open-angle glaucoma will spend the rest of their lives putting one, two or even three different kinds of drops in every day. Unfortunately, all of these drops will not only be inconvenient, but potentially very expensive. The iStent Trabecular Micro-Bypass Stent is designed to reduce eye pressure and patients can have it done at the same time they have cataract surgery.

iStent: the world's smallest medical implant delivers big results in mild-to-moderate open-angle glaucoma.

While mild-to-moderate open-angle glaucoma is very common, many people are unaware of their condition, especially in the early stages, when their vision may be unaffected. In many people, open-angle glaucoma is characterized by an increase in the intraocular pressure (IOP) of your eye. This pressure is caused by the buildup of fluid within the eye. Too much fluid raises pressure, which can cause the gradual loss of vision. And while glaucoma moves slowly, its damage is irreparable.

The world's tiniest medical device—iStent—is 20,000 times smaller than the intraocular lenses (IOL) used in your cataract surgery. But the size of iStent is only part of its story. By increasing the eye's ability to drain fluid, this technology is designed to reduce the pressure in your eye.

((BOX DATA COPY OR HIGHLIGHT))

In a U.S. clinical study, 68% of glaucoma patients who received iStent remained medication free at 12 months while sustaining a target IOP of ≤ 21 mm Hg vs. only 50% of patients who underwent cataract surgery alone.

For more information, please contact our patient advisor by phone at 330-747-2733 or by email at info@eyecareassociates.com.

The intent of this handout is to educate users about eye care. Information found on www.eyecareassociates.com is not intended to replace medical advice. Questions about treatment information should be addressed by your physician.